TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39304604

Group type: EXPERIMENTAL
Intervention: Exercise (home-based, individually tailored, moderate intensity, progressive walking, and resistance training)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active control (nutrition education)
Number of subjects: 19
Study: 39304797

Group type: COMPARATOR
Intervention: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m) and bicalutamide (50 mg/OD)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m), bicalutamide (50 mg/OD), and dutasteride (0.5 mg/OD)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin, bicalutamide, and dutasteride (0.5 mg/OD) in patients with disease progression after prior CAB therapy
Number of subjects: 98
Study: 39304918

Group type: EXPERIMENTAL
Intervention: telephone-delivered psychotherapy (t-CETA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: standard in-person treatment as usual
Number of subjects: 20
Study: 39304930

Group type: EXPERIMENTAL
Intervention: HD-tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study: 39304956

Group type: EXPERIMENTAL
Intervention: Low Socioeconomic Status (SES)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Reserve capacity (helplessness, self-efficacy, social support)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Negative emotions (stress and depressive symptoms)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: SES
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 106
Study: 39305031

Group type: EXPERIMENTAL
Intervention: Fast-acting insulin therapy
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Model prediction using 196 features including baseline HbA1c, SMBG, sex, etc.
Number of subjects: 467
Study: 39305035

Group type: EXPERIMENTAL
Intervention: Individualised comprehensive physical therapy
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Follow-up for extended period (average, 30.71 ± 10.86 months)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 286
Study: 39305089

Group type: EXPERIMENTAL
Intervention: Survey participants' willingness to pay for the program
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Factors influencing enrollment
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Barriers to enrollment for uninterested individuals
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Facilitators for interested individuals
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Awareness of the DPP prior to the study
Number of subjects: 299
Study: 39305160

Group type: EXPERIMENTAL
Intervention: vosoritide (15 μg/kg/day)
Number of subjects: 119
Study: 39305340

Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based intervention with moderate exercise (PB+Ex)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 169
Study: 39305436

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ato) 80 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Atomoxetine and spironolactone (ato-spiro) 80/50 mg
Number of subjects: 21
Study: 39305441

Group type: EXPERIMENTAL
Intervention: Relacorilant (100-200 mg/day for up to 12 weeks or 250-400 mg/day for up to 16 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Surgery (biochemical remission)
Number of subjects: 34
Study: 39305459

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 112
Study: 39305562

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cells
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cytokine release syndrome (CRS) treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Immune effector cell-associated neurotoxicity syndrome (ICANS) treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 6
Study: 39305680

Group type: EXPERIMENTAL
Intervention: Parentbot - a Digital healthcare Assistant
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 118
Study: 39305754

Group type: EXPERIMENTAL
Intervention: Weight loss dietary intervention (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-transplanted subjects (control group)
Number of subjects: 0
Study: 39305808

Group type: EXPERIMENTAL
Intervention: Fentanyl test strips (FTS)
Number of subjects: 509
Study: 39305910

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by two cycles of 200 mg intravenous PD-1 inhibitor, tislelizumab, plus platinum-based chemotherapy.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) followed by immunochemotherapy.
Number of subjects: 46
Study: 39305913

Group type: COMPARATOR
Intervention: Glucocorticoids alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Glucocorticoids in combination with immunosuppressive agents or intravenous immunoglobulin
Number of subjects: 64
Study: 39306190

Group type: EXPERIMENTAL
Intervention: Young Women's Intervention (educational intervention for young women with newly diagnosed breast cancer and their oncologists)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Young Women's Intervention
Number of subjects: 312

Group type: COMPARATOR
Intervention: Contact-time control physical activity intervention
Number of subjects: 312
Study: 39306346

Group type: EXPERIMENTAL
Intervention: Apixaban at a reduced dose of 2.5 mg two times per day
Number of subjects: 178

Group type: COMPARATOR
Intervention: Warfarin therapy adjusted to INR target (2-3)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 178
Study: 39306349

Group type: EXPERIMENTAL
Intervention: Qure.ai's 'qXR' software for prioritising chest X-ray interpretation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care CXRs interpretation without qXR software.
Number of subjects: 0
Study: 39306350

Group type: EXPERIMENTAL
Intervention: First-line cessation medications
Number of subjects: 8144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Increased tobacco regulation
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Lower GDP and more affordable cigarette pricing relative to a country's GDP
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Country-level variables (GDP, cigarette relative income price, MPOWER score)
Number of subjects: 8144
Study: 39306468

Group type: EXPERIMENTAL
Intervention: Liver transplantation plus chemotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 94
Study: 39306585

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg i.v. every 2 weeks or every 3 weeks for ≤2 years
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (≥94 weeks)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Modified PFS for pembrolizumab
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Second-course pembrolizumab
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles
Number of subjects: 834

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 834
Study: 39306592

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD) treatment for OSA, two-piece adjustable appliances, standardized protocol, duration of six years.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD) treatment for OSA.
Number of subjects: 112
Study: 39306601

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg twice daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Amphetamine-dextroamphetamine 20 mg twice daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 44
Study: 39306665

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 39306704

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 144
Study: 39306798

Group type: COMPARATOR
Intervention: BQT (bismuth quadruple therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, bismuth 220 mg, tetracycline 400 mg q.i.d, metronidazole 400 mg q.i.d
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: PBMn (minocycline-containing therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, minocycline 50 mg q.i.d, metronidazole 400 mg q.i.d
Number of subjects: 823
Study: 39306923

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every three weeks
Number of subjects: 18
Study: 39307144

Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 300 mg twice daily
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 600 mg twice daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 39307151

Group type: EXPERIMENTAL
Intervention: Evobrutinib (45 mg twice per day)
Number of subjects: 2290

Group type: COMPARATOR
Intervention: Teriflunomide (14 mg once per day)
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 2290

Group type: COMPARATOR
Intervention: Teriflunomide
Number of subjects: 2290
Study: 39307154

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg once a day
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Trazodone 200 mg once a day
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 530
Study: 39307186

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2028
Study: 39307188

Group type: EXPERIMENTAL
Intervention: Milk protein and milk carbohydrate (MPMC)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Milk protein and vegetable carbohydrate (MPVC)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Vegetable protein and milk carbohydrate (VPMC)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Vegetable-based food (VPVC)
Number of subjects: 413
Study: 39307204

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 150

Group type: COMPARATOR
Intervention: Men
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 150
Study: 39307402

Group type: EXPERIMENTAL
Intervention: EndoZip device (robotic endoscopic suturing)
Number of subjects: 45
Study: 39307479

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index ≥15 events/h.
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in HF patients with preserved ejection fraction.
Number of subjects: 1927

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in HF patients with reduced ejection fraction.
Number of subjects: 1927

Group type: COMPARATOR
Intervention: Patients without heart failure (HF).
Number of subjects: 1927
Study: 39307596

Group type: EXPERIMENTAL
Intervention: CP + PRP
Number of subjects: 87

Group type: COMPARATOR
Intervention: CP
Number of subjects: 87
Study: 39307840

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 215
Study: 39308140

Group type: EXPERIMENTAL
Intervention: Transcatheter ductal artery stenting (DAS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Surgical systemic-to-pulmonary shunt (SPS)
Number of subjects: 236
Study: 39308371

Group type: EXPERIMENTAL
Intervention: Transcatheter shunt implantation
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 508
Study: 39308652

Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 102
Study: 39308871

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 39308936

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Intervention (TLI) for both dyadic partners (Case 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Therapeutic Lifestyle Intervention (TLI) for SCI partner only (Case 2)
Number of subjects: 10
Study: 39308991

Group type: EXPERIMENTAL
Intervention: 10kHz spinal cord stimulation (SCS)
Number of subjects: 144
Study: 39309246

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle intervention (TLI) based on the Diabetes Prevention Program (DPP) including circuit resistance training, a Mediterranean-style calorie-restricted diet, and tailored behavioral support.
Number of subjects: 20
Study: 39309477

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 39309608

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study: 39309627

Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sham Acupressure (SA)
Number of subjects: 114
Study: 39309703

Group type: EXPERIMENTAL
Intervention: AVATAR-based video immersion with radiation therapy
Number of subjects: 81
Study: 39309726

Group type: EXPERIMENTAL
Intervention: Personalised remote speech therapy for 8 weeks
Number of subjects: 214

Group type: COMPARATOR
Intervention: No intervention (waiting list design)
Number of subjects: 214
Study: 39309747

Group type: EXPERIMENTAL
Intervention: Abdominal compressions alone (AC-CPR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard chest compression CPR (S-CPR)
Number of subjects: 11
Study: 39310045

Group type: EXPERIMENTAL
Intervention: CONNECTDROP® Medication Event Monitoring System (MEMS) paired with a smartphone application
Number of subjects: 31
Study: 39310667

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP; ∼38% of daily intake as protein)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal-protein diet (NP; ∼15% of daily intake as protein)
Number of subjects: 16
Study: 39310666

Group type: EXPERIMENTAL
Intervention: OC+P (50 g prunes daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: OC (not consuming prunes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-OC (control group not using OCs)
Number of subjects: 90
Study: 39310769

Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrates (BMACs) from knee-OA patients; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 39311092

Group type: EXPERIMENTAL
Intervention: Transcatheter ductal artery stenting (DAS)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Surgical systemic-to-pulmonary shunt (SPS)
Number of subjects: 236
Study: 39311164

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation protocol (RN4HTx)
Number of subjects: 19
Study: 39311330

Group type: EXPERIMENTAL
Intervention: AI algorithm for assessing dental panoramic radiographs (DPRs)
Number of subjects: 35
Study: 39311502

Group type: EXPERIMENTAL
Intervention: Ultrathin sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting Nobori stent (N-BES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with diabetes mellitus
Number of subjects: 0
Study: 39311597

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) 600 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 194
Study: 39311813

Group type: EXPERIMENTAL
Intervention: Distress tolerance (DT)
Number of subjects: 0
Study: 39311825

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 152

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 152
Study: 39311941

Group type: EXPERIMENTAL
Intervention: Subvastus (SV) approach
Number of subjects: 17

Group type: COMPARATOR
Intervention: Medial parapatellar (MP) approach
Number of subjects: 17
Study: 39312248

Group type: EXPERIMENTAL
Intervention: Pain interference
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Tribal identity
Number of subjects: 514

Group type: COMPARATOR
Intervention: Control for age, gender, food insecurity, anxiety symptoms, and depressive symptoms
Number of subjects: 514
Study: 39312291

Group type: EXPERIMENTAL
Intervention: Chatbot-led support combined with counselor-led support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (brief face-to-face cessation advice and group cessation support led by a chatbot)
Number of subjects: 0
Study: 39312301

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (no TTM)
Number of subjects: 141
Study: 39312389

Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Number of subjects: 4489

Group type: EXPERIMENTAL
Intervention: Removable ankle support
Number of subjects: 4489

Group type: COMPARATOR
Intervention: Physical therapy interventions
Number of subjects: 4489
Study: 39312625

Group type: EXPERIMENTAL
Intervention: Tactile massage (TM) for 15 minutes, twice a week for 4 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 55
Study: 39312715

Group type: EXPERIMENTAL
Intervention: PEEK retainers
Number of subjects: 45

Group type: COMPARATOR
Intervention: DSC retainers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PEEK and DSC retainers
Number of subjects: 45
Study: 39312766

Group type: EXPERIMENTAL
Intervention: TOGETHER-YA intervention via website
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Usability testing of TOGETHER-YA website
Number of subjects: 7
Study: 39312771

Group type: EXPERIMENTAL
Intervention: Home-based PrEP (HB-PrEP) option for 2 of 3 triannual PrEP follow-up visits.
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 458
Study: 39312920

Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine induction
Number of subjects: 93
Study: 39313221

Group type: EXPERIMENTAL
Intervention: soticlestat 300 mg twice daily
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: soticlestat N-oxide metabolite plasma concentrations
Number of subjects: 33

Group type: COMPARATOR
Intervention: soticlestat in Part 2
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: soticlestat at therapeutic doses
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: soticlestat in scenarios of high clinical exposures
Number of subjects: 33
Study: 39313222

Group type: EXPERIMENTAL
Intervention: Registered nurse understaffing
Number of subjects: 213910

Group type: EXPERIMENTAL
Intervention: Nurse assistant understaffing
Number of subjects: 213910
Study: 39313281

Group type: EXPERIMENTAL
Intervention: Elective and emergency paediatric surgery
Number of subjects: 0
Study: 39313282

Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 80
Study: 39313286

Group type: EXPERIMENTAL
Intervention: Acustimulation combined with pharmacological prophylaxis
Number of subjects: 302

Group type: COMPARATOR
Intervention: Sham stimulation combined with pharmacological prophylaxis
Number of subjects: 302
Study: 39313288

Group type: COMPARATOR
Intervention: Standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Number of subjects: 10
Study: 39313302

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg Q4W
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112
Study: 39313307

Group type: EXPERIMENTAL
Intervention: TraditionCART
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: InstanCART
Number of subjects: 22
Study: 39313594

Group type: EXPERIMENTAL
Intervention: Encorafenib (Enco) + Cetuximab (Cetux) ± Binimetinib (Bini)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab (Cetux) + chemotherapy
Number of subjects: 0
Study: 39313860

Group type: EXPERIMENTAL
Intervention: Prophylactic capsular tension ring (CTR) implantation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-CTR group
Number of subjects: 110
Study: 39313857

Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (CoronaVac®) co-administered with inactivated enterovirus type 71 vaccine (Inlive®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 39314107

Group type: EXPERIMENTAL
Intervention: Pharmacologic agents (e.g., botulinum toxin type A, injectable fillers, chemical peels)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 39314125

Group type: EXPERIMENTAL
Intervention: HepB-BD in addition to HepB3 (group U4)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Standard HepB3 vaccine series (group U3)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: HepB-BD and HepB3 (group E4)
Number of subjects: 281
Study: 39314260

Group type: EXPERIMENTAL
Intervention: Zilucoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or standard of care)
Number of subjects: 0
Study: 39314261

Group type: EXPERIMENTAL
Intervention: High-intensity statin treatment
Number of subjects: 57
Study: 39314676

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) proteomics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum proteomics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AHC clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal serum analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CM-to-EM reversion analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 0
Study: 39314770

Group type: EXPERIMENTAL
Intervention: Blood Pressure (BP) categories
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Blood Pressure (BP) categories (specifically hypertension grade 1)
Number of subjects: 1213
Study: 39315230

Group type: COMPARATOR
Intervention: Monofocal theta tACS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifocal in-phase theta tACS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross-frequency stimulations
Number of subjects: 0
Study: 39315253

Group type: COMPARATOR
Intervention: GlobalConsent educational program
Number of subjects: 0
Study: 39315334

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 19615

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 19615

Group type: COMPARATOR
Intervention: Unvaccinated control
Number of subjects: 19615